Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: A review

Fabiola Atzeni, Piercarlo Sarzi-Puttini, Andrea Doria, Luca Iaccarino, Franco Capsoni

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

TNF-α is a crucial cytokine in the establishment and maintenance of inflammation in multiple autoimmune and non-autoimmune disorders. A number of large placebo-controlled trials have shown that infliximab, a chimeric monoclonal antibody against TNF-α, is effective and well-tolerated in patients with Crohn's disease and rheumatoid arthritis (RA) and has become a widely used treatment for these diseases. More recent controlled trials have also shown the effectiveness of TNF-α blockers in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The results of clinical trials, open-label studies, and case studies indicate that TNF inhibitors (alone or in combination with other protocols) look very promising for the treatment of a variety of other conditions, including uveitis, sarcoidosis, Sjögren's syndrome (SS), Behçet's syndrome, vasculitis, and graft versus host disease. There is a rationale for using TNF blockade even in systemic lupus erythematosus, a prototype of autoantibody-mediated disease, and a pilot study seems to confirm this potential effective approach. The neutralisation of TNF might therefore play a role in the treatment of many autoimmune and non-autoimmune disorders other than Crohn's disease or RA. We here review the current and prospective roles of infliximab in the treatment of autoimmune diseases and other conditions that do not currently have FDA or EMEA approval.

Original languageEnglish
Pages (from-to)144-152
Number of pages9
JournalAutoimmunity Reviews
Volume4
Issue number3
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Off-Label Use
Crohn Disease
Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Uveitis
Graft vs Host Disease
Therapeutics
Sarcoidosis
Vasculitis
Psoriasis
Systemic Lupus Erythematosus
Autoantibodies
Autoimmune Diseases
Monoclonal Antibodies
Placebos
Maintenance
Clinical Trials
Cytokines
Inflammation

Keywords

  • Autoimmune and nonautoimmune disorders
  • Biologic agents
  • Infliximab
  • TNF inhibitors
  • TNF-α

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Potential off-label use of infliximab in autoimmune and non-autoimmune diseases : A review. / Atzeni, Fabiola; Sarzi-Puttini, Piercarlo; Doria, Andrea; Iaccarino, Luca; Capsoni, Franco.

In: Autoimmunity Reviews, Vol. 4, No. 3, 03.2005, p. 144-152.

Research output: Contribution to journalArticle

Atzeni, F, Sarzi-Puttini, P, Doria, A, Iaccarino, L & Capsoni, F 2005, 'Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: A review', Autoimmunity Reviews, vol. 4, no. 3, pp. 144-152. https://doi.org/10.1016/j.autrev.2004.08.004
Atzeni, Fabiola ; Sarzi-Puttini, Piercarlo ; Doria, Andrea ; Iaccarino, Luca ; Capsoni, Franco. / Potential off-label use of infliximab in autoimmune and non-autoimmune diseases : A review. In: Autoimmunity Reviews. 2005 ; Vol. 4, No. 3. pp. 144-152.
@article{a6a80707e300400688460f2d8a81eec4,
title = "Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: A review",
abstract = "TNF-α is a crucial cytokine in the establishment and maintenance of inflammation in multiple autoimmune and non-autoimmune disorders. A number of large placebo-controlled trials have shown that infliximab, a chimeric monoclonal antibody against TNF-α, is effective and well-tolerated in patients with Crohn's disease and rheumatoid arthritis (RA) and has become a widely used treatment for these diseases. More recent controlled trials have also shown the effectiveness of TNF-α blockers in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The results of clinical trials, open-label studies, and case studies indicate that TNF inhibitors (alone or in combination with other protocols) look very promising for the treatment of a variety of other conditions, including uveitis, sarcoidosis, Sj{\"o}gren's syndrome (SS), Beh{\cc}et's syndrome, vasculitis, and graft versus host disease. There is a rationale for using TNF blockade even in systemic lupus erythematosus, a prototype of autoantibody-mediated disease, and a pilot study seems to confirm this potential effective approach. The neutralisation of TNF might therefore play a role in the treatment of many autoimmune and non-autoimmune disorders other than Crohn's disease or RA. We here review the current and prospective roles of infliximab in the treatment of autoimmune diseases and other conditions that do not currently have FDA or EMEA approval.",
keywords = "Autoimmune and nonautoimmune disorders, Biologic agents, Infliximab, TNF inhibitors, TNF-α",
author = "Fabiola Atzeni and Piercarlo Sarzi-Puttini and Andrea Doria and Luca Iaccarino and Franco Capsoni",
year = "2005",
month = "3",
doi = "10.1016/j.autrev.2004.08.004",
language = "English",
volume = "4",
pages = "144--152",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Potential off-label use of infliximab in autoimmune and non-autoimmune diseases

T2 - A review

AU - Atzeni, Fabiola

AU - Sarzi-Puttini, Piercarlo

AU - Doria, Andrea

AU - Iaccarino, Luca

AU - Capsoni, Franco

PY - 2005/3

Y1 - 2005/3

N2 - TNF-α is a crucial cytokine in the establishment and maintenance of inflammation in multiple autoimmune and non-autoimmune disorders. A number of large placebo-controlled trials have shown that infliximab, a chimeric monoclonal antibody against TNF-α, is effective and well-tolerated in patients with Crohn's disease and rheumatoid arthritis (RA) and has become a widely used treatment for these diseases. More recent controlled trials have also shown the effectiveness of TNF-α blockers in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The results of clinical trials, open-label studies, and case studies indicate that TNF inhibitors (alone or in combination with other protocols) look very promising for the treatment of a variety of other conditions, including uveitis, sarcoidosis, Sjögren's syndrome (SS), Behçet's syndrome, vasculitis, and graft versus host disease. There is a rationale for using TNF blockade even in systemic lupus erythematosus, a prototype of autoantibody-mediated disease, and a pilot study seems to confirm this potential effective approach. The neutralisation of TNF might therefore play a role in the treatment of many autoimmune and non-autoimmune disorders other than Crohn's disease or RA. We here review the current and prospective roles of infliximab in the treatment of autoimmune diseases and other conditions that do not currently have FDA or EMEA approval.

AB - TNF-α is a crucial cytokine in the establishment and maintenance of inflammation in multiple autoimmune and non-autoimmune disorders. A number of large placebo-controlled trials have shown that infliximab, a chimeric monoclonal antibody against TNF-α, is effective and well-tolerated in patients with Crohn's disease and rheumatoid arthritis (RA) and has become a widely used treatment for these diseases. More recent controlled trials have also shown the effectiveness of TNF-α blockers in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The results of clinical trials, open-label studies, and case studies indicate that TNF inhibitors (alone or in combination with other protocols) look very promising for the treatment of a variety of other conditions, including uveitis, sarcoidosis, Sjögren's syndrome (SS), Behçet's syndrome, vasculitis, and graft versus host disease. There is a rationale for using TNF blockade even in systemic lupus erythematosus, a prototype of autoantibody-mediated disease, and a pilot study seems to confirm this potential effective approach. The neutralisation of TNF might therefore play a role in the treatment of many autoimmune and non-autoimmune disorders other than Crohn's disease or RA. We here review the current and prospective roles of infliximab in the treatment of autoimmune diseases and other conditions that do not currently have FDA or EMEA approval.

KW - Autoimmune and nonautoimmune disorders

KW - Biologic agents

KW - Infliximab

KW - TNF inhibitors

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=16844381697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844381697&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2004.08.004

DO - 10.1016/j.autrev.2004.08.004

M3 - Article

C2 - 15823500

AN - SCOPUS:16844381697

VL - 4

SP - 144

EP - 152

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 3

ER -